Skip to main content
. Author manuscript; available in PMC: 2020 Jan 15.
Published in final edited form as: Clin Cancer Res. 2018 Sep 4;25(2):573–583. doi: 10.1158/1078-0432.CCR-18-0655

Table 1.

Clinical characteristics of 84 FLT3-ITD-positive AML patients.

n %
All Subjects 84 -
Sex
      Male 43 51.2
      Female 41 48.8
Age at Diagnosis
      < 60 54 64.3
      ≥ 60 30 35.7
Disease Status
      Newly DiagnosedA 58 69.0
      Relapse 26 31.0
Induction Chemotherapy
     Yes 82 97.6
     No 2 2.40
FLT3 Inhibitor Treated
     Yes 68 81.0
     No 16 19.0
FLT3 Inhibitor Characterization
     Type 1 23 33.8
     Type 2 29 42.7
     Both 16 23.5
Allogeneic Transplant
     Yes 54 64.3
     No 30 35.7
Disease Status at initiation of FLT3i
     Remission 32 38.1
     Active Disease 52 61.9
A

Of the 58 newly diagnosed patients, none had favorable cytogenetics, 49 had intermediate risk, 6 had adverse risk, 1 had no growth, and 2 did not have cytogenetics performed.